Human dermal fibroblast (HDF) (HDF)

Human dermal fibroblasts (HDFs) are the predominant cell type in the dermis, essential for maintaining skin integrity through the synthesis of extracellular matrix (ECM) components such as collagen and elastin (NIH, 2023). These cells are critical mediators of the wound healing process, where they migrate to the site of injury and differentiate into myofibroblasts to facilitate tissue contraction (PubMed, 2012). In pathological conditions like systemic sclerosis or keloids, HDFs exhibit persistent activation, leading to the overproduction of ECM and subsequent tissue fibrosis (StatPearls, 2023). Conversely, in aging skin, HDFs show reduced proliferative capacity and decreased collagen production, contributing to wrinkle formation and skin fragility (Journal of Dermatological Science, 2018). While HDFs are a cellular population rather than a single molecular target, they are the primary site of action for drugs like nintedanib and pirfenidone, which inhibit tyrosine kinase and TGF-beta signaling to mitigate fibrotic responses (PubMed, 2019). Understanding HDF biology is vital for developing therapies for wound care, aesthetics, and systemic fibrotic diseases.

Other names

Dermal fibroblastSkin fibroblastHDF

Drugs typically modulate fibroblast activity by inhibiting signaling pathways such as TGF-beta or PDGF, or by activating nuclear receptors like the Retinoic acid receptor to regulate collagen synthesis and cell proliferation (PubMed, 2019).